Literature DB >> 10619950

A double-blind randomized controlled trial and economic evaluation of transurethral resection vs contact laser vaporization for benign prostatic enlargement: a 3-year follow-up.

S R Keoghane1, K C Lawrence, A M Gray, H A Doll, A M Hancock, K Turner, M E Sullivan, O Dyar, D Cranston.   

Abstract

OBJECTIVE: To evaluate the effect of contact laser prostate surgery in the treatment of benign prostatic hyperplasia. PATIENTS AND METHODS: A prospective double-blind randomized controlled trial of transurethral resection of the prostate (TURP) and contact laser prostatectomy was conducted, with an economic evaluation of both procedures. The primary outcome measure was the change in the American Urologic Association symptom score, with secondary outcome measures being the peak urinary flow rate, treatment-related complications, re-operation rate and health service costs.
RESULTS: The perioperative blood loss and transfusion requirements were statistically significantly lower for laser prostatectomy than for TURP. There was no clinically significant difference between TURP and contact laser prostatectomy in the mean change in symptom scores and flow rates. There were distinct perioperative advantages in favour of the contact laser treatment, but some disadvantages in terms of re-catheterization and re-operation rates.
CONCLUSIONS: Contact laser prostatectomy is a valid treatment for benign prostatic hypertrophy. The performance of contact laser prostatectomy as day-case surgery would have cost advantages to the National Health Service.

Entities:  

Mesh:

Year:  2000        PMID: 10619950     DOI: 10.1046/j.1464-410x.2000.00407.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  16 in total

Review 1.  Benign prostatic hyperplasia.

Authors:  M J Barry; C G Roehrborn
Journal:  BMJ       Date:  2001-11-03

2.  Holmium laser enucleation of the prostate: a paradigm shift in benign prostatic hyperplasia surgery.

Authors:  Tevita F Aho
Journal:  Ther Adv Urol       Date:  2013-10

Review 3.  In 2013, holmium laser enucleation of the prostate (HoLEP) may be the new 'gold standard'.

Authors:  Simon van Rij; Peter J Gilling
Journal:  Curr Urol Rep       Date:  2012-12       Impact factor: 3.092

4.  The economics of benign prostatic hyperplasia and lower urinary tract symptoms in the United States.

Authors:  David A Taub; John T Wei
Journal:  Curr Urol Rep       Date:  2006-07       Impact factor: 3.092

Review 5.  Changing therapeutic regimens in benign prostatic hyperplasia. Clinical and economic considerations.

Authors:  H J Stoevelaar; J McDonnell
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 6.  Urethral stricture following endoscopic prostate surgery: a systematic review and meta-analysis of prospective, randomized trials.

Authors:  Giacomo Maria Pirola; Daniele Castellani; Ee Jean Lim; Marcelo Langer Wroclawski; Dong Le Quy Nguyen; Marilena Gubbiotti; Emanuele Rubilotta; Vinson Wai-Shun Chan; Mariela Corrales; Esther García Rojo; Thomas R W Herrmann; Jeremy Yuen-Chun Teoh; Vineet Gauhar
Journal:  World J Urol       Date:  2022-02-13       Impact factor: 4.226

7.  Energy delivery systems for treatment of benign prostatic hyperplasia: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2006-08-01

Review 8.  Laser treatment of symptomatic benign prostatic hyperplasia.

Authors:  Ehab A Elzayat; Mostafa M Elhilali
Journal:  World J Urol       Date:  2006-03-04       Impact factor: 4.226

Review 9.  The use of lasers in benign prostatic enlargement.

Authors:  T A McNicholas; S Singh
Journal:  Curr Urol Rep       Date:  2000-08       Impact factor: 3.092

10.  Bladder neck stenosis after transurethral prostate surgery: a systematic review and meta-analysis.

Authors:  Daniele Castellani; Marcelo Langer Wroclawski; Giacomo Maria Pirola; Vineet Gauhar; Emanuele Rubilotta; Vinson Wai-Shun Chan; Bryan Kwun-Chung Cheng; Marilena Gubbiotti; Andrea Benedetto Galosi; Thomas R W Herrmann; Jeremy Yuen-Chun Teoh
Journal:  World J Urol       Date:  2021-05-11       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.